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Primary cutaneous mucinous carcinoma (PCMC) is a rare mucin-producing malignancy derived from epi-thelial glandular structures, first described in 1952 
by Lennox et al.1–4 The tumor most often presents in the 
sixth or seventh decade with a predilection for the head 
and neck.5–7 It tends to locally recur, but rarely metasta-
sizes.1,2,5 Since its initial description, literature documents 
various case series and reports of PCMC. After identifica-
tion of a cutaneous mucin-producing neoplasm, it is es-
sential to differentiate the primary cutaneous form from 
an underlying metastatic malignancy because the progno-
sis and management differ drastically.1–4
BACKGROUND
In 2005, Kazakov et al.5 published a series of mucinous 
lesions, 37 of which were PCMC with 24 metastatic adeno-
carcinomas. The average age of presentation in this series 
was 65.2 years. Of the 37 PCMC identified, 95% presented 
on the head and neck and 41% were on the scalp. Addi-
tionally, there are a few case series (Table 1) such as the 
meta-analysis by Kamalpour et al.6 containing data from 
1952 to 2010, which document 159 PCMC with the major-
ity in the head and neck area.
One of the greatest challenges in identifying PCMC 
is differentiating it from an underlying metastatic 
process.2–5,8–10 The presentation of the primary cutaneous 
form both histologically and grossly appears nearly iden-
tical to metastatic adenocarcinoma. The tumor cells may 
stain positive immunohistochemically (IHC) for specific 
markers of breast, lung, ovary, prostate, and gastrointestinal 
(GI) tumors that will carry a poor prognosis.1–4 Research in 
differentiating these processes via IHC markers has been 
pursued. In a small series by Levy et al.,3 PCMC and breast 
metastatic mucinous carcinoma to the skin stained posi-
tive for CK7, whereas primary colorectal adenocarcinoma 
stained positive for CK20. Authors concluded that CK20 
was an appropriate IHC marker to differentiate GI ad-
enocarcinomas; however, the other markers were neither 
sensitive nor specific enough to differentiate breast from 
the primary cutaneous forms. Literature supports that the 
presence of an in situ component favors PCMC, whereas 
location on the chest wall or in the axilla tends to favor a 
breast primary.5
In a 16-year retrospective study at a single cancer cen-
ter, 51 cases of metastatic adenocarcinoma from an inter-
nal primary were identified.8 In the majority of them, the 
cutaneous metastatic lesion presented within 3 years fol-
lowing initial diagnosis; however, in 6 cases, the cutaneous 
metastasis was the initial presentation of an underlying 
malignancy. These findings support the importance of a 
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Summary: Primary cutaneous mucinous carcinoma (PCMC) is a rare mucin-pro-
ducing malignancy derived from epithelial glandular structures. The literature re-
garding this topic is mostly in the form of case reports and case series. PCMC tends 
to present in the elderly with predilection for the head and neck and on initial 
assessment it can be easily mistaken for a simple inclusion cyst. Although PCMC 
is often indolent in nature, in rare instances it can metastasize and should remain 
a differential diagnosis in a selected population. The significance in identifying 
PCMC is reliably differentiating it from metastatic mucinous adenocarcinoma. We 
present a review of literature and case of PCMC on the scalp of a 67-year-old female. 
(Plast Reconstr Surg Glob Open 2018;6:e1761; doi: 10.1097/GOX.0000000000001761; 
 Published online 16 April 2018.)
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thorough workup for underlying malignancy upon recog-
nition of a cutaneous mucinous neoplasm.
Treatment modalities of PCMC include surgical exci-
sion or Mohs procedure, with local recurrence rates up to 
40%.6 A poor outcome, defined by recurrence or metasta-
sis, was associated with younger age at presentation, lesion 
> 1.5 cm, and lesions presenting on the trunk.6 Alternative-
ly, a favorable outcome was associated with individuals who 
presented at an older age, with smaller lesions, and lesions 
on the head and neck.6 In rare instances, radiation alone, or 
in combination with chemotherapy, has been attempted in 
patients with distant metastasis of PCMC with little success.6,10
CASE PRESENTATION
A 67-year-old Caucasian female with medical history of 
inflammatory bowel disease presented for evaluation of an 
enlarging, palpable scalp mass for the past year. She re-
ports that in addition to growth, the lesion started to cause 
migraine headaches. On physical examination, a mobile 
mass measuring 5 × 3 cm was observed on the right tempo-
ral scalp region. The skin was thickened but no ulceration, 
bleeding, or sinus tracts were appreciated. Based on clini-
cal evaluation, the patient was scheduled for lesion exci-
sion and closure of a suspected epidermal inclusion cyst.
The patient was brought to the operating room for sur-
gical excision of lesion. However, instead of revealing the 
expected cyst wall, the opening incision revealed a pink, 
nonwalled mucinous substance. Due to the unexpected 
findings, the surgeon completed an excisional biopsy with 
primary closure (Fig. 1).
Hematoxylin and eosin histologic examination re-
vealed an infiltrative tumor center in the dermis and 
 extending into the subcutis and margins of resection. The 
tumor was composed of pools of mucin separated by thin 
fibrous septae with mildly atypical epithelial clusters and 
duct formation floating amongst the mucin (Fig. 2). IHC 
analysis showed the tumor cells to be strongly CK7-positive 
(Fig. 3) while CK 20-negative. Based on these findings, the 
histologic differential diagnosis included PCMC versus 
Table 1. PCMC in the Literature
Author Cases
Age Range  
(Average)
Head  
and Neck
Trunk/ 
Other Outcomes
Breiting et al.2 15 43–83 (64) 14 1 1 patient required chemotherapy for recurrence, 1 regional 
lymph node metastasis
Mendoza and Helwig4 14 8–76 (51.3) 9 5 6 recurrences, 1 regional lymph node metastasis
Kazakov et al.5 37 31–89 (65) 35 2 7 reexcisions due to positive margins, 5 recurrences
Kamalpour et al.6 159 63.5 137 22 15 treated with Mohs: 2 (13%) recurrences; 136 treated with 
excision: 46 (34%) recurrences
Al Beteddini et al.7 1 61 1  Mohs surgery
Choi et al.9 1 49 1  5 mm excision margin, no recurrence
Hanna et al.10 1 74 1  Recurrence following surgical excision, subsequently treated 
with radiation
Fig. 1. Intraoperative excised scalp specimen revealing transition 
between the skin and lesion.
Fig. 2. Hematoxylin and eosin staining 100× magnification of ex-
cised specimen.
Fig. 3. specimen showing CK 7-positive immunohistochemical 
staining.
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metastatic mucinous carcinoma, especially of the breast 
due to CK7 positivity. Therefore, the patient was referred 
to oncology for a thorough oncologic workup.
Mammography showed no abnormalities, excluding 
breast as primary; however, positron emission tomography 
scan revealed hypermetabolic activity suspicious for rectal 
adenocarcinoma. Following discussion with her gastroen-
terologist and oncologist, the increased activity observed 
from the positron emission tomography scan was deter-
mined to be secondary to her history of inflammatory 
bowel disease. This diagnosis was biopsy proven, thereby 
ruling out a GI malignant primary. After discussion with 
the pathologist, comprehensive assessment of IHC CK20-
negative staining further supported the excised lesion 
as a PCMC. Literature on resection margins for PCMC 
is scarce. The decision for margin reexcision was based 
on management of malignant skin cancers.9,10 Reexcision 
was performed with a 1.0-cm margin, leading to a 6 × 4 cm 
defect that was closed via complex wound closure. The fi-
nal pathology reported negative margins. The patient is 6 
months postoperative with no recurrences and follows in 
conjunction with oncology.
DISCUSSION
This case demonstrates the relatively rare phenom-
enon of PCMC presentation (estimated < 50 documented 
cases with scalp presentation). PCMC should be in the 
differential diagnosis of cutaneous lesions, specifically in 
patients of older age with lesions of the head and neck. Lit-
erature describes metastatic cutaneous adenocarcinoma 
with primary sites of malignancy in the lungs, breast, and 
viscera. Although IHC stains aid in the workup of primary 
cutaneous versus metastatic mucinous adenocarcinoma, 
they should not be relied on exclusively to determine the 
definitive diagnosis. Upon discovery of a cutaneous lesion 
with histology, suggesting mucinous adenocarcinoma, a 
thorough oncologic workup is warranted to rule out an 
underlying malignancy. For the future, given the rarity of 
this tumor, it is important to maintain continuous docu-
mentation especially regarding margin resection to track 
outcomes such as recurrence and metastasis.
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